Bei Hu1, Ryan Jacobs1, Nilanjan Ghosh2. 1. Department of Hematologic Malignancies and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. 2. Department of Hematologic Malignancies and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Nilanjan.Ghosh@atriumhealth.org.
Abstract
PURPOSE OF THE REVIEW: The ligation of PD-1 with PD-L1 activates a critical immune checkpoint leading to T cell dysfunction, exhaustion, and tolerance. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse the immune checkpoint, releasing the brake on T cell responses. We provide a comprehensive review of the literature on the activity of checkpoint inhibitors in lymphoma. RECENT FINDINGS: We discuss the latest findings with checkpoint inhibitors in lymphoma and new promising studies incorporating these agents. Classical Hodgkin lymphoma is very sensitive to PD1/PL1 blockade due to genetic alterations in 9p21.1 leading to the high expression of PDL1. Although majority of NHLs have a much lower sensitivity to PD1/PDL1 blockade, a few subtypes such as primary CNS lymphoma, primary testicular lymphoma, primary mediastinal lymphoma harbor 9p21.1 alterations making them vulnerable to PD1 blockade. EBV-associated lymphomas have a virally mediated increased expression of PDL1 making them sensitive to PD1 blockade.
PURPOSE OF THE REVIEW: The ligation of PD-1 with PD-L1 activates a critical immune checkpoint leading to T cell dysfunction, exhaustion, and tolerance. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse the immune checkpoint, releasing the brake on T cell responses. We provide a comprehensive review of the literature on the activity of checkpoint inhibitors in lymphoma. RECENT FINDINGS: We discuss the latest findings with checkpoint inhibitors in lymphoma and new promising studies incorporating these agents. Classical Hodgkin lymphoma is very sensitive to PD1/PL1 blockade due to genetic alterations in 9p21.1 leading to the high expression of PDL1. Although majority of NHLs have a much lower sensitivity to PD1/PDL1 blockade, a few subtypes such as primary CNS lymphoma, primary testicular lymphoma, primary mediastinal lymphoma harbor 9p21.1 alterations making them vulnerable to PD1 blockade. EBV-associated lymphomas have a virally mediated increased expression of PDL1 making them sensitive to PD1 blockade.
Authors: Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell Journal: Blood Date: 2017-04-19 Impact factor: 22.113
Authors: Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu Journal: Lancet Oncol Date: 2013-12-11 Impact factor: 41.316
Authors: D Rossille; I Azzaoui; A L Feldman; M J Maurer; G Labouré; M Parrens; C Pangault; T M Habermann; S M Ansell; B K Link; K Tarte; T E Witzig; T Lamy; S L Slager; M Roussel; N Milpied; J R Cerhan; T Fest Journal: Leukemia Date: 2017-01-27 Impact factor: 11.528
Authors: Jacob P Smeltzer; Jason M Jones; Steven C Ziesmer; Deanna M Grote; Bing Xiu; Kay M Ristow; Zhi Zhang Yang; Grzegorz S Nowakowski; Andrew L Feldman; James R Cerhan; Anne J Novak; Stephen M Ansell Journal: Clin Cancer Res Date: 2014-04-11 Impact factor: 12.531
Authors: David D W Twa; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; Anja Mottok; King L Tan; Graham W Slack; Jay Gunawardana; Raymond S Lim; Andrew W McPherson; Robert Kridel; Adele Telenius; David W Scott; Kerry J Savage; Sohrab P Shah; Randy D Gascoyne; Christian Steidl Journal: Blood Date: 2014-02-04 Impact factor: 22.113
Authors: Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps Journal: N Engl J Med Date: 2015-12-06 Impact factor: 91.245
Authors: Bjoern Chapuy; Margaretha G M Roemer; Chip Stewart; Yuxiang Tan; Ryan P Abo; Liye Zhang; Andrew J Dunford; David M Meredith; Aaron R Thorner; Ekaterina S Jordanova; Gang Liu; Friedrich Feuerhake; Matthew D Ducar; Gerald Illerhaus; Daniel Gusenleitner; Erica A Linden; Heather H Sun; Heather Homer; Miyuki Aono; Geraldine S Pinkus; Azra H Ligon; Keith L Ligon; Judith A Ferry; Gordon J Freeman; Paul van Hummelen; Todd R Golub; Gad Getz; Scott J Rodig; Daphne de Jong; Stefano Monti; Margaret A Shipp Journal: Blood Date: 2015-12-23 Impact factor: 22.113
Authors: R Parody; I Sánchez-Ortega; A Mussetti; B Patiño; M Arnan; H Pomares; E González-Barca; S Mercadal; C Boqué; C Maluquer; I Carro; M Peña; V Clapés; S Verdesoto; G Bustamante; A C Oliveira; C Baca; E Cabezudo; C Talarn; L Escoda; S Ortega; N García; M Isabel González-Medina; Mar Sánchez-Salmerón; C Fusté; J Villa; E Carreras; E Domingo-Domènech; A Sureda Journal: Bone Marrow Transplant Date: 2021-10-28 Impact factor: 5.483
Authors: Maciej Kujawski; Mark Sherman; Susanta Hui; Darren Zuro; Wen-Hui Lee; Paul Yazaki; Anakim Sherman; Barbara Szpikowska; Junie Chea; Desiree Lasiewski; Kofi Poku; Harry Li; David Colcher; Jeffrey Wong; John E Shively Journal: Oncoimmunology Date: 2020-02-14 Impact factor: 8.110